Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: A cost effectiveness study

Mostrar otras versiones (1)

BACKGROUND: To compare the costs and effects of paliperidone extended release (ER), a new pharmaceutical treatment for the management of schizophrenia, with the most frequently prescribed oral treatments in Greece (namely risperidone, olanzapine, quetiapine, aripiprazole and ziprasidone) over a 1-ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Geitona, Maria, Kousoulakou, Hara, Ollandezos, Markos, Athanasakis, Kostas, Papanicolaou, Sotiria, Kyriopoulos, Ioannis
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2553072/
https://www.ncbi.nlm.nih.gov/pubmed/18755025
http://dx.doi.org/10.1186/1744-859X-7-16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2553072/
https://www.ncbi.nlm.nih.gov/pubmed/18755025
http://dx.doi.org/10.1186/1744-859X-7-16

Ejemplares similares